Adverse pathology predicts metastasis, death in patients with prostate cancer

“Adverse pathology is a clear predictor of long-term outcomes for patients,” says Eric A. Klein, MD.

In this video, Eric A. Klein, MD, discusses the background and findings of the recent Urologic Oncology: Seminars and Original Investigations study, Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy, for which he served as senior author. Klein is the emeritus chair of the Cleveland Clinic Glickman Urological & Kidney Institute.